Metronomic chemotherapy, which is defined by the frequent, repetitive
administration of chemotherapeutic drugs at relatively low doses, and without
prolonged drug-free break, is an emerging strategy to fight cancer. Initially
thought to act by targeting tumour angiogenesis, additional mechanisms have
been recently unveiled and metronomic chemotherapy is now considered to
represent a form of multi-targeted therapy. Despite representing a genuine
alternative for advanced and/or high-risk cancer therapy, the development of
metronomic approaches in pediatric oncology are still in the early stage. The lack
of large scale state-of-the-art clinical trials, issues regarding terminology and the
limited understanding of the complex and intertwined mechanisms of action of
metronomic treatments hinder the visibility and credibility of this field of
research. On March 18th -19th 2010, the 2nd International Workshop on
Metronomic and Anti-Angiogenic Chemotherapy in Pediatric Oncology was held
in Marseille, France, and brought together clinicians, basic scientists, physicianscientists, trainees and students from all around the world. The main aim of this
international meeting was to provide a unique forum to i) reflect on the major
advances that have been made in this field of research since its creation, ii)
communicate results from the most recent clinical trials and pre-clinical studies,
iii) discuss the current and future challenges of the field, iv) standardize
terminology and v) set forth a solid framework for future collaborative biological
and clinical studies. The present report documents the main pre-clinical and
clinical data that were presented in the keynote and best abstract sessions and
delivers the key messages from the meeting

full report of the meeting available freely in Translational Oncology : click here

Moving forward with metronomic scheduling of anti-cancer treatment:
Meeting report of the 2nd international workshop on metronomic and antiangiogenic chemotherapy in paediatric oncology
Pasquier E, Kieran M.W, Sterba J, Shaked Y, Baruchel S, Oberlin O, Kivivuori M.S, Peyrl A, Diawarra M, Casanova M, Zacharoulis S, Vassal G, Berthold F, Verschuur A, André N.